-
1
-
-
0032858487
-
Phase iii multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma
-
Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS et al (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17(9):2745-2751
-
(1999)
J Clin Oncol
, vol.17
, Issue.9
, pp. 2745-2751
-
-
Chapman, P.B.1
Einhorn, L.H.2
Meyers, M.L.3
Saxman, S.4
Destro, A.N.5
Panageas, K.S.6
-
2
-
-
0033024863
-
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
-
Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7):2105-2116
-
(1999)
J Clin Oncol
, vol.17
, Issue.7
, pp. 2105-2116
-
-
Atkins, M.B.1
Lotze, M.T.2
Dutcher, J.P.3
Fisher, R.I.4
Weiss, G.5
Margolin, K.6
-
3
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949-954
-
(2002)
Nature
, vol.417
, Issue.6892
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
Stephens, P.4
Edkins, S.5
Clegg, S.6
-
4
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516
-
(2011)
N Engl J Med
, vol.364
, Issue.26
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
Haanen, J.B.4
Ascierto, P.5
Larkin, J.6
-
5
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
-
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839): 358-365
-
(2012)
Lancet
, vol.380
, Issue.9839
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
Jouary, T.4
Gutzmer, R.5
Millward, M.6
-
6
-
-
84865092227
-
Metric phase iii study: Efficacy of trametinib (t), a potent and selective mek inhibitor (meki), in progression-free survival (pfs) and overall survival (os), compared with chemotherapy C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma MM
-
suppl):(abstr LBA8509
-
Robert C, Flaherty K, Hersey P, Nathan P, CGarbe C, Milhem M, et al (2012) METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM). J Clin Oncol 30(suppl):(abstr LBA8509
-
(2012)
J Clin Oncol
, vol.30
-
-
Robert, C.1
Flaherty, K.2
Hersey, P.3
Nathan, P.4
Cgarbe, C.5
Milhem, M.6
-
7
-
-
27844567142
-
Distinct sets of genetic alterations in melanoma
-
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20):2135-2147
-
(2005)
N Engl J Med
, vol.353
, Issue.20
, pp. 2135-2147
-
-
Curtin, J.A.1
Fridlyand, J.2
Kageshita, T.3
Patel, H.N.4
Busam, K.J.5
Kutzner, H.6
-
8
-
-
58149216961
-
Oncogenic mutations in GNAQ occur early in uveal melanoma
-
PMCID 2634606
-
Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM et al (2008) Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 49(12):5230-5234, PMCID: 2634606
-
(2008)
Invest Ophthalmol Vis Sci
, vol.49
, Issue.12
, pp. 5230-5234
-
-
Onken, M.D.1
Worley, L.A.2
Long, M.D.3
Duan, S.4
Council, M.L.5
Bowcock, A.M.6
-
9
-
-
59049107421
-
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
-
PMCID 2696133
-
Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM et al (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457(7229): 599-602, PMCID: 2696133
-
(2009)
Nature
, vol.457
, Issue.7229
, pp. 599-602
-
-
Van Raamsdonk, C.D.1
Bezrookove, V.2
Green, G.3
Bauer, J.4
Gaugler, L.5
O'Brien, J.M.6
-
10
-
-
78651446131
-
Mutations in GNA11 in uveal melanoma
-
Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T et al (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363(23):2191-2199
-
(2010)
N Engl J Med
, vol.363
, Issue.23
, pp. 2191-2199
-
-
Van Raamsdonk, C.D.1
Griewank, K.G.2
Crosby, M.B.3
Garrido, M.C.4
Vemula, S.5
Wiesner, T.6
-
11
-
-
78649700287
-
Frequent mutation of BAP1 in metastasizing uveal melanomas
-
Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA et al (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009):1410-1413
-
(2010)
Science
, vol.330
, Issue.6009
, pp. 1410-1413
-
-
Harbour, J.W.1
Onken, M.D.2
Roberson, E.D.3
Duan, S.4
Cao, L.5
Worley, L.A.6
-
12
-
-
0141619356
-
Lack of BRAF mutations in uveal melanoma
-
Rimoldi D, Salvi S, Lienard D, Lejeune FJ, Speiser D, Zografos L et al (2003) Lack of BRAF mutations in uveal melanoma. Cancer Res 63(18):5712-5715
-
(2003)
Cancer Res
, vol.63
, Issue.18
, pp. 5712-5715
-
-
Rimoldi, D.1
Salvi, S.2
Lienard, D.3
Lejeune, F.J.4
Speiser, D.5
Zografos, L.6
-
13
-
-
0037562846
-
Lack of BRAF mutation in primary uveal melanoma
-
Cohen Y, Goldenberg-Cohen N, Parrella P, Chowers I, Merbs SL, Péer J et al (2003) Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci 44(7):2876-2878
-
(2003)
Invest Ophthalmol Vis Sci
, vol.44
, Issue.7
, pp. 2876-2878
-
-
Cohen, Y.1
Goldenberg-Cohen, N.2
Parrella, P.3
Chowers, I.4
Merbs, S.L.5
Péer, J.6
-
14
-
-
0038146846
-
Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas
-
PMCID 2741050
-
Edmunds SC, Cree IA, Di Nicolantonio F, Hungerford JL, Hurren JS, Kelsell DP (2003) Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer 88(9):1403-1405, PMCID: 2741050
-
(2003)
Br J Cancer
, vol.88
, Issue.9
, pp. 1403-1405
-
-
Edmunds, S.C.1
Cree, I.A.2
Di Nicolantonio, F.3
Hungerford, J.L.4
Hurren, J.S.5
Kelsell, D.P.6
-
15
-
-
39549115096
-
Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma
-
Maat W, Kilic E, Luyten GP, de Klein A, Jager MJ, Gruis NA et al (2008) Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. Invest Ophthalmol Vis Sci 49(1): 23-27
-
(2008)
Invest Ophthalmol Vis Sci
, vol.49
, Issue.1
, pp. 23-27
-
-
Maat, W.1
Kilic, E.2
Luyten, G.P.3
De Klein, A.4
Jager, M.J.5
Gruis, N.A.6
-
16
-
-
33749021085
-
Somatic activation of KIT in distinct subtypes of melanoma
-
Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24(26): 4340-4346
-
(2006)
J Clin Oncol
, vol.24
, Issue.26
, pp. 4340-4346
-
-
Curtin, J.A.1
Busam, K.2
Pinkel, D.3
Bastian, B.C.4
-
17
-
-
58149260596
-
KIT gene mutations and copy number in melanoma subtypes
-
Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J et al (2008) KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 14(21):6821-6828
-
(2008)
Clin Cancer Res
, vol.14
, Issue.21
, pp. 6821-6828
-
-
Beadling, C.1
Jacobson-Dunlop, E.2
Hodi, F.S.3
Le C Warrick, A.4
Patterson, J.5
-
18
-
-
0022626874
-
A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family
-
Besmer P, Murphy JE, George PC, Qiu FH, Bergold PJ, Lederman L et al (1986) A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 320(6061): 415-421
-
(1986)
Nature
, vol.320
, Issue.6061
, pp. 415-421
-
-
Besmer, P.1
Murphy, J.E.2
George, P.C.3
Qiu, F.H.4
Bergold, P.J.5
Lederman, L.6
-
19
-
-
2742529418
-
Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand
-
PMCID 553789
-
Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ et al (1987) Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6(11):3341-3351, PMCID: 553789
-
(1987)
EMBO J
, vol.6
, Issue.11
, pp. 3341-3351
-
-
Yarden, Y.1
Kuang, W.J.2
Yang-Feng, T.3
Coussens, L.4
Munemitsu, S.5
Dull, T.J.6
-
20
-
-
77954216079
-
Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics
-
Woodman SE, Davies MA (2010) Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80(5):568-574
-
(2010)
Biochem Pharmacol
, vol.80
, Issue.5
, pp. 568-574
-
-
Woodman, S.E.1
Davies, M.A.2
-
21
-
-
0027089718
-
Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2
-
PMCID 275535
-
Huang EJ, Nocka KH, Buck J, Besmer P (1992) Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2. Mol Biol Cell 3(3):349-362, PMCID: 275535
-
(1992)
Mol Biol Cell
, vol.3
, Issue.3
, pp. 349-362
-
-
Huang, E.J.1
Nocka, K.H.2
Buck, J.3
Besmer, P.4
-
22
-
-
9744246909
-
Signal transduction via the stem cell factor receptor/c-Kit
-
Ronnstrand L (2004) Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci 61(19-20):2535-2548
-
(2004)
Cell Mol Life Sci
, vol.61
, Issue.19-20
, pp. 2535-2548
-
-
Ronnstrand, L.1
-
23
-
-
0028917884
-
Membrane-bound steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form
-
Miyazawa K, Williams DA, Gotoh A, Nishimaki J, Broxmeyer HE, Toyama K (1995) Membrane-bound steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. Blood 85(3):641-649
-
(1995)
Blood
, vol.85
, Issue.3
, pp. 641-649
-
-
Miyazawa, K.1
Williams, D.A.2
Gotoh, A.3
Nishimaki, J.4
Broxmeyer, H.E.5
Toyama, K.6
-
24
-
-
0018625422
-
Hereditary anemias of the mouse: A review for geneticists
-
Russell ES (1979) Hereditary anemias of the mouse: A review for geneticists. Adv Genet 20: 357-459
-
(1979)
Adv Genet
, vol.20
, pp. 357-459
-
-
Russell, E.S.1
-
25
-
-
0031699406
-
Stage-specific expression of the Kit receptor and its ligand (KL) during male gametogenesis in the mouse: A Kit-KL interaction critical for meiosis
-
Vincent S, Segretain D, Nishikawa S, Nishikawa SI, Sage J, Cuzin F et al (1998) Stage-specific expression of the Kit receptor and its ligand (KL) during male gametogenesis in the mouse: A Kit-KL interaction critical for meiosis. Development 125(22):4585-4593
-
(1998)
Development
, vol.125
, Issue.22
, pp. 4585-4593
-
-
Vincent, S.1
Segretain, D.2
Nishikawa, S.3
Nishikawa, S.I.4
Sage, J.5
Cuzin, F.6
-
26
-
-
0032983371
-
Activating c-kit gene mutations in human germ cell tumors
-
PMCID 1876773
-
Tian Q, Frierson HF Jr, Krystal GW, Moskaluk CA (1999) Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 154(6):1643-1647, PMCID: 1876773
-
(1999)
Am J Pathol
, vol.154
, Issue.6
, pp. 1643-1647
-
-
Tian, Q.1
Frierson Jr., H.F.2
Krystal, G.W.3
Moskaluk, C.A.4
-
27
-
-
33745726073
-
Development, migration, and survival of mast cells
-
PMCID 1490026
-
Okayama Y, Kawakami T (2006) Development, migration, and survival of mast cells. Immunol Res 34(2):97-115, PMCID: 1490026
-
(2006)
Immunol Res
, vol.34
, Issue.2
, pp. 97-115
-
-
Okayama, Y.1
Kawakami, T.2
-
28
-
-
0028796630
-
W/kit gene required for interstitial cells of cajal and for intestinal pacemaker activity
-
Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A (1995) W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373(6512):347-349
-
(1995)
Nature
, vol.373
, Issue.6512
, pp. 347-349
-
-
Huizinga, J.D.1
Thuneberg, L.2
Kluppel, M.3
Malysz, J.4
Mikkelsen, H.B.5
Bernstein, A.6
-
29
-
-
80051981588
-
C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation
-
PMCID: 3161112
-
Phung B, Sun J, Schepsky A, Steingrimsson E, Ronnstrand L (2011) C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation. PLoS One 6(8):e24064, PMCID: 3161112
-
(2011)
PLoS One
, vol.6
, Issue.8
-
-
Phung, B.1
Sun, J.2
Schepsky, A.3
Steingrimsson, E.4
Ronnstrand, L.5
-
30
-
-
57049091596
-
Transcriptional and signaling regulation in neural crest stem cellderived melanocyte development: Do all roads lead to Mitf?
-
Hou L, Pavan WJ (2008) Transcriptional and signaling regulation in neural crest stem cellderived melanocyte development: Do all roads lead to Mitf? Cell Res 18(12):1163-1176
-
(2008)
Cell Res
, vol.18
, Issue.12
, pp. 1163-1176
-
-
Hou, L.1
Pavan, W.J.2
-
31
-
-
0028957223
-
Mutations at the W locus affect survival of neural crestderived melanocytes in the mouse
-
Cable J, Jackson IJ, Steel KP (1995) Mutations at the W locus affect survival of neural crestderived melanocytes in the mouse. Mech Dev 50(2-3):139-150
-
(1995)
Mech Dev
, vol.50
, Issue.2-3
, pp. 139-150
-
-
Cable, J.1
Jackson, I.J.2
Steel, K.P.3
-
32
-
-
0023694835
-
The protooncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus
-
Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A (1988) The protooncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335(6185):88-89
-
(1988)
Nature
, vol.335
, Issue.6185
, pp. 88-89
-
-
Chabot, B.1
Stephenson, D.A.2
Chapman, V.M.3
Besmer, P.4
Bernstein, A.5
-
33
-
-
0026541532
-
Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism
-
PMCID 1682440
-
Spritz RA, Giebel LB, Holmes SA (1992) Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism. Am J Hum Genet 50(2):261-269, PMCID: 1682440
-
(1992)
Am J Hum Genet
, vol.50
, Issue.2
, pp. 261-269
-
-
Spritz, R.A.1
Giebel, L.B.2
Holmes, S.A.3
-
34
-
-
0024280901
-
The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene
-
Geissler EN, Ryan MA, Housman DE (1988) The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55(1):185-192
-
(1988)
Cell
, vol.55
, Issue.1
, pp. 185-192
-
-
Geissler, E.N.1
Ryan, M.A.2
Housman, D.E.3
-
35
-
-
33646153073
-
Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes
-
Alexeev V, Yoon K (2006) Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 126(5):1102-1110
-
(2006)
J Invest Dermatol
, vol.126
, Issue.5
, pp. 1102-1110
-
-
Alexeev, V.1
Yoon, K.2
-
36
-
-
66749132873
-
Stem cell factor-KIT signalling plays a pivotal role in regulating pigmentation in mammalian hair
-
Hachiya A, Sriwiriyanont P, Kobayashi T, Nagasawa A, Yoshida H, Ohuchi A et al (2009) Stem cell factor-KIT signalling plays a pivotal role in regulating pigmentation in mammalian hair. J Pathol 218(1):30-39
-
(2009)
J Pathol
, vol.218
, Issue.1
, pp. 30-39
-
-
Hachiya, A.1
Sriwiriyanont, P.2
Kobayashi, T.3
Nagasawa, A.4
Yoshida, H.5
Ohuchi, A.6
-
37
-
-
65149096689
-
Gain-of-function mutation of KIT ligand on melanin synthesis causes familial progressive hyperpigmentation
-
PMCID 2680999
-
Wang ZQ, Si L, Tang Q, Lin D, Fu Z, Zhang J et al (2009) Gain-of-function mutation of KIT ligand on melanin synthesis causes familial progressive hyperpigmentation. Am J Hum Genet 84(5):672-677, PMCID: 2680999
-
(2009)
Am J Hum Genet
, vol.84
, Issue.5
, pp. 672-677
-
-
Wang, Z.Q.1
Si, L.2
Tang, Q.3
Lin, D.4
Fu, Z.5
Zhang, J.6
-
38
-
-
0030459095
-
Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential
-
Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD et al (1996) Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13(11):2339-2347
-
(1996)
Oncogene
, vol.13
, Issue.11
, pp. 2339-2347
-
-
Huang, S.1
Luca, M.2
Gutman, M.3
McConkey, D.J.4
Langley, K.E.5
Lyman, S.D.6
-
39
-
-
0026793058
-
Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor
-
Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A, Ullrich A (1992) Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 52(2):197-201
-
(1992)
Int J Cancer
, vol.52
, Issue.2
, pp. 197-201
-
-
Natali, P.G.1
Nicotra, M.R.2
Winkler, A.B.3
Cavaliere, R.4
Bigotti, A.5
Ullrich, A.6
-
40
-
-
0030765407
-
Proto-oncogene c-kit expression in malignant melanoma: Protein loss with tumor progression
-
Montone KT, van Belle P, Elenitsas R, Elder DE (1997) Proto-oncogene c-kit expression in malignant melanoma: Protein loss with tumor progression. Mod Pathol 10(9):939-944
-
(1997)
Mod Pathol
, vol.10
, Issue.9
, pp. 939-944
-
-
Montone, K.T.1
Van Belle, P.2
Elenitsas, R.3
Elder, D.E.4
-
41
-
-
0026518279
-
Loss of c-kit expression in cultured melanoma cells
-
Lassam N, Bickford S (1992) Loss of c-kit expression in cultured melanoma cells. Oncogene 7(1):51-56
-
(1992)
Oncogene
, vol.7
, Issue.1
, pp. 51-56
-
-
Lassam, N.1
Bickford, S.2
-
42
-
-
0141958794
-
Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array
-
Shen SS, Zhang PS, Eton O, Prieto VG (2003) Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 30(9):539-547
-
(2003)
J Cutan Pathol
, vol.30
, Issue.9
, pp. 539-547
-
-
Shen, S.S.1
Zhang, P.S.2
Eton, O.3
Prieto, V.G.4
-
43
-
-
21044460131
-
Lack of clinical efficacy of imatinib in metastatic melanoma
-
PMCID 2362005
-
Ugurel S, Hildenbrand R, Zimpfer A, La Rosee P, Paschka P, Sucker A et al (2005) Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92(8):1398-1405, PMCID: 2362005
-
(2005)
Br J Cancer
, vol.92
, Issue.8
, pp. 1398-1405
-
-
Ugurel, S.1
Hildenbrand, R.2
Zimpfer, A.3
La Rosee, P.4
Paschka, P.5
Sucker, A.6
-
44
-
-
33646268037
-
Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: Signifi cant toxicity with no clinical efficacy
-
Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F et al (2006) Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: Signifi cant toxicity with no clinical efficacy. Cancer 106(9): 2005-2011
-
(2006)
Cancer
, vol.106
, Issue.9
, pp. 2005-2011
-
-
Wyman, K.1
Atkins, M.B.2
Prieto, V.3
Eton, O.4
McDermott, D.F.5
Hubbard, F.6
-
45
-
-
50249141632
-
Phase II trial of imatinib mesylate in patients with metastatic melanoma
-
PMCID 2528157
-
Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH et al (2008) Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99(5):734-740, PMCID: 2528157
-
(2008)
Br J Cancer
, vol.99
, Issue.5
, pp. 734-740
-
-
Kim, K.B.1
Eton, O.2
Davis, D.W.3
Frazier, M.L.4
McConkey, D.J.5
Diwan, A.H.6
-
46
-
-
34249018869
-
Gastrointestinal stromal tumour
-
Rubin BP, Heinrich MC, Corless CL (2007) Gastrointestinal stromal tumour. Lancet 369(9574):1731-1741
-
(2007)
Lancet
, vol.369
, Issue.9574
, pp. 1731-1741
-
-
Rubin, B.P.1
Heinrich, M.C.2
Corless, C.L.3
-
47
-
-
20844433223
-
Progressionfree survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial
-
Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY et al (2004) Progressionfree survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364(9440):1127-1134
-
(2004)
Lancet
, vol.364
, Issue.9440
, pp. 1127-1134
-
-
Verweij, J.1
Casali, P.G.2
Zalcberg, J.3
LeCesne, A.4
Reichardt, P.5
Blay, J.Y.6
-
48
-
-
0032523833
-
Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization
-
Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D (1998) Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58(10):2170-2175
-
(1998)
Cancer Res
, vol.58
, Issue.10
, pp. 2170-2175
-
-
Bastian, B.C.1
LeBoit, P.E.2
Hamm, H.3
Brocker, E.B.4
Pinkel, D.5
-
49
-
-
16544371910
-
Prevalence of KIT expression in human tumors
-
Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S et al (2004) Prevalence of KIT expression in human tumors. J Clin Oncol 22(22):4514-4522
-
(2004)
J Clin Oncol
, vol.22
, Issue.22
, pp. 4514-4522
-
-
Went, P.T.1
Dirnhofer, S.2
Bundi, M.3
Mirlacher, M.4
Schraml, P.5
Mangialaio, S.6
-
50
-
-
3242794909
-
Detection of c-kit-activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis
-
Willmore C, Holden JA, Zhou L, Tripp S, Wittwer CT, Layfield LJ (2004) Detection of c-kit-activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis. Am J Clin Pathol 122(2): 206-216
-
(2004)
Am J Clin Pathol
, vol.122
, Issue.2
, pp. 206-216
-
-
Willmore, C.1
Holden, J.A.2
Zhou, L.3
Tripp, S.4
Wittwer, C.T.5
Layfield, L.J.6
-
51
-
-
33646145930
-
BRAF and c-kit gene copy number in mutation-positive malignant melanoma
-
Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ (2006) BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol 37(5):520-527
-
(2006)
Hum Pathol
, vol.37
, Issue.5
, pp. 520-527
-
-
Willmore-Payne, C.1
Holden, J.A.2
Hirschowitz, S.3
Layfield, L.J.4
-
52
-
-
34250335270
-
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition
-
Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP et al (2007) L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121(2):257-264
-
(2007)
Int J Cancer
, vol.121
, Issue.2
, pp. 257-264
-
-
Antonescu, C.R.1
Busam, K.J.2
Francone, T.D.3
Wong, G.C.4
Guo, T.5
Agaram, N.P.6
-
53
-
-
37549021543
-
C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma
-
Rivera RS, Nagatsuka H, Gunduz M, Cengiz B, Gunduz E, Siar CH et al (2008) C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 452(1):27-32
-
(2008)
Virchows Arch
, vol.452
, Issue.1
, pp. 27-32
-
-
Rivera, R.S.1
Nagatsuka, H.2
Gunduz, M.3
Cengiz, B.4
Gunduz, E.5
Siar, C.H.6
-
54
-
-
57449093330
-
Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas
-
PMCID 2607233
-
Satzger I, Schaefer T, Kuettler U, Broecker V, Voelker B, Ostertag H et al (2008) Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer 99(12):2065-2069, PMCID: 2607233
-
(2008)
Br J Cancer
, vol.99
, Issue.12
, pp. 2065-2069
-
-
Satzger, I.1
Schaefer, T.2
Kuettler, U.3
Broecker, V.4
Voelker, B.5
Ostertag, H.6
-
55
-
-
58149461573
-
Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas
-
Ashida A, Takata M, Murata H, Kido K, Saida T (2009) Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 124(4):862-868
-
(2009)
Int J Cancer
, vol.124
, Issue.4
, pp. 862-868
-
-
Ashida, A.1
Takata, M.2
Murata, H.3
Kido, K.4
Saida, T.5
-
56
-
-
70350668375
-
Correlation between KIT expression and KIT mutation in melanoma: A study of 173 cases with emphasis on the acral-lentiginous/mucosal type
-
Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J et al (2009) Correlation between KIT expression and KIT mutation in melanoma: A study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 22(11):1446-1456
-
(2009)
Mod Pathol
, vol.22
, Issue.11
, pp. 1446-1456
-
-
Torres-Cabala, C.A.1
Wang, W.L.2
Trent, J.3
Yang, D.4
Chen, S.5
Galbincea, J.6
-
57
-
-
79958066836
-
KIT as a therapeutic target in metastatic melanoma
-
Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J et al (2011) KIT as a therapeutic target in metastatic melanoma. JAMA 305(22):2327-2334
-
(2011)
JAMA
, vol.305
, Issue.22
, pp. 2327-2334
-
-
Carvajal, R.D.1
Antonescu, C.R.2
Wolchok, J.D.3
Chapman, P.B.4
Roman, R.A.5
Teitcher, J.6
-
58
-
-
0033619142
-
Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/ MAP kinase pathway and c-fos induction
-
Lennartsson J, Blume-Jensen P, Hermanson M, Ponten E, Carlberg M, Ronnstrand L (1999) Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/ MAP kinase pathway and c-fos induction. Oncogene 18(40):5546-5553
-
(1999)
Oncogene
, vol.18
, Issue.40
, pp. 5546-5553
-
-
Lennartsson, J.1
Blume-Jensen, P.2
Hermanson, M.3
Ponten, E.4
Carlberg, M.5
Ronnstrand, L.6
-
59
-
-
41749118496
-
Molecular pathobiology of gastrointestinal stromal sarcomas
-
Corless CL, Heinrich MC (2008) Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 3:557-586
-
(2008)
Annu Rev Pathol
, vol.3
, pp. 557-586
-
-
Corless, C.L.1
Heinrich, M.C.2
-
60
-
-
79953324920
-
Large-scale analysis of kit aberrations in chinese patients with melanoma
-
Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT et al (2011) Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 17(7):1684-1691
-
(2011)
Clin Cancer Res
, vol.17
, Issue.7
, pp. 1684-1691
-
-
Kong, Y.1
Si, L.2
Zhu, Y.3
Xu, X.4
Corless, C.L.5
Flaherty, K.T.6
-
61
-
-
79955965083
-
Kit amplifi cation and gene mutations in acral/mucosal melanoma in korea
-
Yun J, Lee J, Jang J, Lee EJ, Jang KT, Kim JH et al (2011) KIT amplifi cation and gene mutations in acral/mucosal melanoma in Korea. APMIS 119(6):330-335
-
(2011)
APMIS
, vol.119
, Issue.6
, pp. 330-335
-
-
Yun, J.1
Lee, J.2
Jang, J.3
Lee, E.J.4
Jang, K.T.5
Kim, J.H.6
-
62
-
-
77949406203
-
Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure
-
Handolias D, Salemi R, Murray W, Tan A, Liu W, Viros A et al (2010) Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res 23(2):210-215
-
(2010)
Pigment Cell Melanoma Res
, vol.23
, Issue.2
, pp. 210-215
-
-
Handolias, D.1
Salemi, R.2
Murray, W.3
Tan, A.4
Liu, W.5
Viros, A.6
-
63
-
-
74449089861
-
C-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes
-
Monsel G, Ortonne N, Bagot M, Bensussan A, Dumaz N (2010) c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes. Oncogene 29(2):227-236
-
(2010)
Oncogene
, vol.29
, Issue.2
, pp. 227-236
-
-
Monsel, G.1
Ortonne, N.2
Bagot, M.3
Bensussan, A.4
Dumaz, N.5
-
64
-
-
59449085455
-
Imatinib targeting of kit-mutant oncoprotein in melanoma
-
Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA et al (2008) Imatinib targeting of kit-mutant oncoprotein in melanoma. Clin Cancer Res 14(23):7726-7732
-
(2008)
Clin Cancer Res
, vol.14
, Issue.23
, pp. 7726-7732
-
-
Jiang, X.1
Zhou, J.2
Yuen, N.K.3
Corless, C.L.4
Heinrich, M.C.5
Fletcher, J.A.6
-
65
-
-
68849093078
-
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
-
Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM et al (2009) Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates. Mol Cancer Ther 8(8):2079-2085
-
(2009)
Mol Cancer Ther
, vol.8
, Issue.8
, pp. 2079-2085
-
-
Woodman, S.E.1
Trent, J.C.2
Stemke-Hale, K.3
Lazar, A.J.4
Pricl, S.5
Pavan, G.M.6
-
66
-
-
42949128595
-
Major response to imatinib mesylate in KIT-mutated melanoma
-
Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A et al (2008) Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26(12):2046-2051
-
(2008)
J Clin Oncol
, vol.26
, Issue.12
, pp. 2046-2051
-
-
Hodi, F.S.1
Friedlander, P.2
Corless, C.L.3
Heinrich, M.C.4
Mac Rae, S.5
Kruse, A.6
-
67
-
-
76649108873
-
Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy-case report and review of the literature
-
Satzger I, Kuttler U, Volker B, Schenck F, Kapp A, Gutzmer R (2010) Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy-case report and review of the literature. Dermatology 220(1):77-81
-
(2010)
Dermatology
, vol.220
, Issue.1
, pp. 77-81
-
-
Satzger, I.1
Kuttler, U.2
Volker, B.3
Schenck, F.4
Kapp, A.5
Gutzmer, R.6
-
68
-
-
47249099056
-
Dosedependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
-
Lutzky J, Bauer J, Bastian BC (2008) Dosedependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21(4):492-493
-
(2008)
Pigment Cell Melanoma Res
, vol.21
, Issue.4
, pp. 492-493
-
-
Lutzky, J.1
Bauer, J.2
Bastian, B.C.3
-
69
-
-
74349095692
-
Melanoma from bench to bedside: Meeting report from the 6th international melanoma congress
-
Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E et al (2010) Melanoma from bench to bedside: Meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res 23:14-26
-
(2010)
Pigment Cell Melanoma Res
, vol.23
, pp. 14-26
-
-
Fisher, D.E.1
Barnhill, R.2
Hodi, F.S.3
Herlyn, M.4
Merlino, G.5
Medrano, E.6
-
70
-
-
57049109807
-
Complete response of stage IV anal mucosal melanoma expressing kit val560asp to the multikinase inhibitor sorafenib
-
Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P (2008) Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 5(12):737-740
-
(2008)
Nat Clin Pract Oncol
, vol.5
, Issue.12
, pp. 737-740
-
-
Quintas-Cardama, A.1
Lazar, A.J.2
Woodman, S.E.3
Kim, K.4
Ross, M.5
Hwu, P.6
-
71
-
-
76649118476
-
Response to sunitinib in Chinese KIT -mutated metastatic mucosal melanoma
-
abstract
-
Zhu Y, Si L, Kong Y, Chi Z, Yuan X, Cui C, et al. (2009) Response to sunitinib in Chinese KIT -mutated metastatic mucosal melanoma. J Clin Oncol 27(abstract):e20017
-
(2009)
J Clin Oncol
, vol.27
-
-
Zhu, Y.1
Si, L.2
Kong, Y.3
Chi, Z.4
Yuan, X.5
Cui, C.6
-
72
-
-
84857760658
-
Sunitinib therapy for melanoma patients with KIT mutations
-
Minor DR, Kashani-Sabet M, Garrido M, O'Day SJ, Hamid O, Bastian BC (2012) Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 18(5): 1457-1463
-
(2012)
Clin Cancer Res
, vol.18
, Issue.5
, pp. 1457-1463
-
-
Minor, D.R.1
Kashani-Sabet, M.2
Garrido, M.3
O'Day, S.J.4
Hamid, O.5
Bastian, B.C.6
-
73
-
-
79955500900
-
A phase 2 trial of dasatinib in advanced melanoma
-
Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB et al (2011) A phase 2 trial of dasatinib in advanced melanoma. Cancer 117(10):2202-2208
-
(2011)
Cancer
, vol.117
, Issue.10
, pp. 2202-2208
-
-
Kluger, H.M.1
Dudek, A.Z.2
McCann, C.3
Ritacco, J.4
Southard, N.5
Jilaveanu, L.B.6
-
74
-
-
84867867288
-
Nilotinib in patients with metastatic melanoma harboring KIT gene aberration
-
Cho JH, Kim KM, Kwon M, Kim JH, Lee J (2011) Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 30(5):2008-2014
-
(2011)
Invest New Drugs
, vol.30
, Issue.5
, pp. 2008-2014
-
-
Cho, J.H.1
Kim, K.M.2
Kwon, M.3
Kim, J.H.4
Lee, J.5
-
75
-
-
84978034236
-
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
-
Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29(10):1239-1246
-
(2011)
J Clin Oncol
, vol.29
, Issue.10
, pp. 1239-1246
-
-
Long, G.V.1
Menzies, A.M.2
Nagrial, A.M.3
Haydu, L.E.4
Hamilton, A.L.5
Mann, G.J.6
-
76
-
-
72549086618
-
Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: An in vitro mutagenesis screen for drug resistance
-
PMCID 2783687
-
Guo T, Hajdu M, Agaram NP, Shinoda H, Veach D, Clarkson BD et al (2009) Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: An in vitro mutagenesis screen for drug resistance. Clin Cancer Res 15(22):6862-6870, PMCID: 2783687
-
(2009)
Clin Cancer Res
, vol.15
, Issue.22
, pp. 6862-6870
-
-
Guo, T.1
Hajdu, M.2
Agaram, N.P.3
Shinoda, H.4
Veach, D.5
Clarkson, B.D.6
-
77
-
-
33750595859
-
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
-
Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24(29):4764-4774
-
(2006)
J Clin Oncol
, vol.24
, Issue.29
, pp. 4764-4774
-
-
Heinrich, M.C.1
Corless, C.L.2
Blanke, C.D.3
Demetri, G.D.4
Joensuu, H.5
Roberts, P.J.6
-
78
-
-
0642368571
-
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
-
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21(23): 4342-4349
-
(2003)
J Clin Oncol
, vol.21
, Issue.23
, pp. 4342-4349
-
-
Heinrich, M.C.1
Corless, C.L.2
Demetri, G.D.3
Blanke, C.D.4
Von Mehren, M.5
Joensuu, H.6
-
79
-
-
41149170835
-
Clinicopathologic profi le of gastrointestinal stromal tumors (gists) with primary kit exon 13 or exon 17 mutations: A multicenter study on 54 cases
-
Lasota J, Corless CL, Heinrich MC, Debiec-Rychter M, Sciot R, Wardelmann E et al (2008) Clinicopathologic profi le of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: A multicenter study on 54 cases. Mod Pathol 21(4):476-484
-
(2008)
Mod Pathol
, vol.21
, Issue.4
, pp. 476-484
-
-
Lasota, J.1
Corless, C.L.2
Heinrich, M.C.3
Debiec-Rychter, M.4
Sciot, R.5
Wardelmann, E.6
-
81
-
-
84863072006
-
Major response to everolimus in melanoma with acquired imatinib resistance
-
Si L, Xu X, Kong Y, Flaherty KT, Chi Z, Cui C et al (2012) Major response to everolimus in melanoma with acquired imatinib resistance. J Clin Oncol 30(4):e37-e40
-
(2012)
J Clin Oncol
, vol.30
, Issue.4
-
-
Si, L.1
Xu, X.2
Kong, Y.3
Flaherty, K.T.4
Chi, Z.5
Cui, C.6
-
82
-
-
77950866918
-
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in kit
-
PMCID 2856012
-
Handolias D, Hamilton AL, Salemi R, Tan A, Moodie K, Kerr L et al (2010) Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 102(8):1219-1223, PMCID: 2856012
-
(2010)
Br J Cancer
, vol.102
, Issue.8
, pp. 1219-1223
-
-
Handolias, D.1
Hamilton, A.L.2
Salemi, R.3
Tan, A.4
Moodie, K.5
Kerr, L.6
|